A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

The immunogenicities of candidate DNA- and modified vaccinia virus Ankara (MVA)-vectored human immunodeficiency virus (HIV) vaccines were evaluated on their own and in a prime-boost regimen in phase I clinical trials in healthy uninfected individuals in the United Kingdom. Given the current lack of...

Full description

Bibliographic Details
Main Authors:	Mwau, M, Cebere, I, Sutton, J, Chikoti, P, Winstone, N, Wee, E, Beattie, T, Chen, Y, Dorrell, L, Mcshane, H, Schmidt, C, Brooks, M, Patel, S, Roberts, J, Conlon, C, Rowland-Jones, S, Bwayo, J, Mcmichael, A, Hanke, T
Format:	Journal article
Language:	English
Published:	2004

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

Similar Items